Abiopharma

🔍 Vickers Philip J. (Executive)

Company: Akebia Therapeutics, Inc. (AKBA)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 214,400 shares of Stock Option (Right to buy) at $1.41 per share (Derivative)
  Date: 2026-04-01 | Code: A | Expires: 2036-04-01 | equity_swap_involved: false | shares_owned_after: 214,400.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program. The Stock Option will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter, subject to the Reporting Person's continued service to the Issuer.